Analytical Data
-
Gene name
IKZF1
- Application
-
Alternative Names
IKZF1；IK1；IKAROS；LYF1；DNA-binding Protein Ikaros
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q13422
-
Expression Region
1-477aa
-
AA Sequence
MDADEGQDMSQVSGKESPPVSDTPDEGDEPMPIPEDLSTTSGGQQSSKSDRVVASNVKVETQSDEENGRACEMNGEECAEDLRMLDASGEKMNGSHRDQGSSALSGVGGIRLPNGKLKCDICGIICIGPNVLMVHKRSHTGERPFQCNQCGASFTQKGNLLRHIKLHSGEKPFKCHLCNYACRRRDALTGHLRTHSVIKEETNHSEMAEDLCKIGSERSLVLDRLASNVAKRKSSMPQKFLGDKGLSDTPYDSSASYEKENEMMKSHVMDQAINNAINYLGAESLRPLVQTPPGGSEVVPVISPMYQLHKPLAEGTPRSNHSAQDSAVENLLLLSKAKLVPSEREASPSNSCQDSTDTESNNEEQRSGLIYLTNHIAPHARNGLSLKEEHRAYDLLRAASENSQDALRVVSTSGEQMKVYKCEHCRVLFLDHVMYTIHMGCHGFRDPFECNMCGYHSQDRYEFSSHITRGEHRFHMS
-
Molecular Weight
56.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IKZF1, also known as IKAROS, is a critical transcription factor involved in the regulation of lymphocyte development and function. Mutations and rearrangements in the IKZF1 gene are frequently observed in various types of hematological malignancies, particularly acute lymphoblastic leukemia (ALL), where they are associated with poor prognosis and resistance to therapy. Research has shown that IKZF1 plays a pivotal role in maintaining the balance between proliferation and differentiation of B and T cell lineages, and its dysfunction often leads to oncogenic transformation. The study of recombinant IKZF1 proteins has gained prominence as these proteins can be used to elucidate the molecular mechanisms underlying its regulatory functions, assess drug interactions, and identify potential therapeutic targets. Advances in recombinant protein technologies have enabled the production of functional IKZF1 proteins for biochemical assays and structural studies, facilitating a deeper understanding of how specific mutations alter its activity. This research is crucial for developing novel treatment strategies that could improve outcomes for patients with IKZF1-related malignancies. Thus, the investigation of IKZF1 recombinant proteins is not only significant for basic scientific knowledge but also holds promise for clinical applications in cancer therapy.
